Status:
WITHDRAWN
The Role of Adrenomedullin on the Outcome of Severe Heart Failure: a Clinical Randomized Study
Lead Sponsor:
Federal University of São Paulo
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
1. Study Hypothesis: * The decrease of plasma adrenomedullin (ADM) concentration by ultrafiltration and isovolumetric hemofiltration in patients with acute III and IV Class New York Heart Associat...
Detailed Description
Testing the hypothesis that adrenomedullin (ADM) is a important peptide in severe heart failure and that is related to clinical condition, we will study the effects of 3 different treatments (clinical...
Eligibility Criteria
Inclusion
- more than two item:
- more than eighteen years of age
- orthopnea
- Chest Rx with cardiomegaly and pulmonary infiltration
- edema
- diuretic resistance
Exclusion
- insulin dependent diabetes
- hepatic cirrhosis
- vascular access problems
- creatinine more than 2,5 mg/dl before acute heart failure
- systemic infection
- aortic stenosis and heart transplantation
- radiologic contrast up to 72 hours prior randomization
- advanced neoplasia
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01154504
Start Date
April 1 2010
End Date
December 1 2012
Last Update
November 4 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto de Cardiologia
Porto Alegre, Rio Grande do Sul, Brazil, 94801970